In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Inpatient versus outpatient introduction of angiotensin receptor neprilysin inhibitor in chronic heart failure patients

Session Poster Session 2

Speaker Mehdi Aleyan

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure – Treatment
  • Session type : Poster Session

Authors : M Aleyan (Lyon,FR), N Mewton (Lyon,FR), C Bergerot (Lyon,FR), L Green (Lyon,FR), E Hugon-Vallet (Lyon,FR), M Ovize (Lyon,FR), L Sebbag (Lyon,FR)

Authors:
M Aleyan1 , N Mewton2 , C Bergerot2 , L Green3 , E Hugon-Vallet3 , M Ovize2 , L Sebbag4 , 1Civils Hospices of Lyon - Lyon - France , 2Hospital Louis Pradel of Bron, Centre d’Investigation Clinique, UMR Inserm 1407 - Lyon - France , 3Hospital Louis Pradel of Bron, Filière Insuffisance Cardiaque, CHU Louis Pradel - Lyon - France , 4Civils Hospices of Lyon, Pôle Transplantation Cardiaque, CHU Louis Pradel - Lyon - France ,

Citation:

BACKGROUND: According to current guidelines, angiotensin receptor neprilysin inhibitors (ARNIs) are indicated in ambulatory patients with chronic heart failure (HF) and reduced ejection fraction (EF).

PURPOSE : To assess the safety and effects of ARNI introduction in HFrEF inpatients compared to outpatients in a retrospective single-center registry.

METHODS : In an observational retrospective and mono-centric registry at our institution we included all HFrEF patients who received a Sacubitril/Valsartan prescription from July 2015 to November 2016 . All patient data was recorded in their medical files at baseline at follow-up at 6 months for safety, and efficacy. Patients were retrospectively classified into 2 groups according to ARNI introduction mode: inpatient or outpatient.

RESULTS : 89 patients were included in our registry: 49 were outpatients and 40 inpatients. Mean systolic blood pressure at ARNI start was similar between outpatients and inpatients (117±15 versus 110±16 mmHg, respectively; p=0.06) as was glomerular filtration rate (GFR) (67.8±26.1 versus 64.0±25.2 ml/min, respectively; p=0.49). At 6 months follow-up, ARNIs had been continued in 90% of the outpatients versus 92% of the inpatients (p=0.79). There was a trend toward more symptomatic hypotension episodes in the inpatient group compared to the outpatient group (30,7% versus 18.6%, respectively; p=0.2) but GFR remained similar between groups (66.8±29 vs 59.5±25 ml/min; p=0.23) and the was no difference in hyperkalemia incidence between the outpatient and inpatient groups (4.7 versus 7.8%, respectively; p=0.56). In both groups, there was a significant improvement in NYHA class and LVEF at 6 months compared to baseline status.

CONCLUSIONS : In a monocentric observational registry, there was no significant difference in safety and efficacy in ARNI prescription between inpatients and outpatients with chronic HFrEF.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are